S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
These 2 carnivore dining stocks gaining on the Ozempic craze
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
This healthcare stock making a buzz with 160% growth
This infrastructure construction stock: Is it ready to pop?
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
How major US stock indexes fared Monday, 2/26/2024
Is Roku worth a second look after the earnings panic selloff?
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
Is The Trade Desk signaling the rebound of digital advertising?
bluebird bio stock is ripe for a 400% institutional short squeeze
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
These 2 carnivore dining stocks gaining on the Ozempic craze
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
This healthcare stock making a buzz with 160% growth
This infrastructure construction stock: Is it ready to pop?
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
How major US stock indexes fared Monday, 2/26/2024
Is Roku worth a second look after the earnings panic selloff?
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
Is The Trade Desk signaling the rebound of digital advertising?
bluebird bio stock is ripe for a 400% institutional short squeeze
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
These 2 carnivore dining stocks gaining on the Ozempic craze
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
This healthcare stock making a buzz with 160% growth
This infrastructure construction stock: Is it ready to pop?
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
How major US stock indexes fared Monday, 2/26/2024
Is Roku worth a second look after the earnings panic selloff?
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
Is The Trade Desk signaling the rebound of digital advertising?
bluebird bio stock is ripe for a 400% institutional short squeeze
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
These 2 carnivore dining stocks gaining on the Ozempic craze
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
This healthcare stock making a buzz with 160% growth
This infrastructure construction stock: Is it ready to pop?
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
How major US stock indexes fared Monday, 2/26/2024
Is Roku worth a second look after the earnings panic selloff?
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
Is The Trade Desk signaling the rebound of digital advertising?
bluebird bio stock is ripe for a 400% institutional short squeeze

3 biotech powerhouses poised to thrive amid sector rebound

Key Points

  • REGN excels with strong sector outperformance and analyst favoritism owing to its diverse product portfolio and impressive gains this year.
  • GILD holds a large weight in the sector ETF and currently hints at a major breakout, making it a key stock to monitor for the sector.
  • ALNY, though short-term underperformance, sustains a stable uptrend backed by bullish analyst sentiments.
  • 5 stocks we like better than Regeneron Pharmaceuticals

Chemist working with blue liquid and futuristic interface showing DNA diagram; learn more about 3 biotech stocks worth pursuing

The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, has lagged the overall market during the year. However, in recent weeks, the sector has enjoyed a significant rally and turnaround off its 52-week lows.

The recent rally in the biotech sector comes when investor optimism and speculation are on the rise, as the overall market and key sectors, like technology and finance, trade in the upper portion of their 52-week range. 

If the newfound support and steady uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader. If that is to happen, an investor armed with a bullish biotech bias might benefit from gaining exposure to some of the ETF’s top holdings with recent and higher timeframe notable strength. 

Let's look closely at three industry-leading biotech stocks displaying notable strength. 

Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals Inc. NASDAQ: REGN is a global company that discovers, develops, manufactures and commercializes medical treatments for various diseases. Its product portfolio includes EYLEA for eye-related conditions, DUPIXENT for dermatitis and asthma, LIBTAYO for skin cancer, Praluent for cholesterol management and KEVZARA for rheumatoid arthritis. Regeneron is the IBB’s fourth-largest holding, with a 7.67% weight in the ETF.

Regeneron Pharmaceuticals overview

Shares of Regeneron have stood out from the rest, vastly outperforming the sector and IBB year-to-date, with its almost 18% year-to-date performance. You'll have difficulty finding a stock within the sector currently displaying as much relative strength as REGN. The stock not only has outperformed on the year, but it's currently trading at the high end of its 52-week range, looking set to expand further on its already impressive gains YTD.


Analysts also favor the stock, as it is among the most-upgraded stocks. Based on 26 analyst ratings, REGN has a consensus rating of "moderate buy" and a price target of $908.12, forecasting an almost 7% upside. Most recently, on December 6, TD Cowen boosted its target from $900 to $1,000, forecasting a nearly 20% upside for the stock. 

Gilead Sciences 

Gilead Sciences Inc. NASDAQ: GILD is a biopharmaceutical company known for pioneering treatments in HIV/AIDS, hepatitis C and other critical health areas. Founded in 1987, they focus on developing innovative medicines to address unmet medical needs worldwide. Gilead is the IBB's third-largest holding, with an 8.18% weighting.

Gilead Sciences overview

Like the overall sector and IBB ETF, shares of Gilead are slightly negative on the year but have enjoyed notable strength in recent weeks. From a technical analysis perspective, GILD has formed a significant bullish consolidation on its daily, dating back to the beginning of the year. Such a lengthy consolidation signals that the breakout might be substantial.

As Gilead maintains such a considerable weight and influence on the IBB and overall sector, keeping tabs on the stock's performance and potential breakout in the coming weeks or months is vital. 

Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc. NASDAQ: ALNY is a biopharmaceutical company specializing in RNA interference (RNAi) therapeutics. Alnylam's focus on harnessing RNAi pathways has led to novel treatments for various conditions, aiming to transform patient care in areas with significant unmet medical needs. ALNY is the 11th-largest holding of the IBB ETF, with a 2.19% weighting. 

While shares of ALNY have performed worse than the sector year-to-date, the stock has impressed over a higher timeframe and remains in a steady uptrend on its higher timeframe

While the market has been bearish ALNY on the year, analysts have remained bullish. So if the renewed strength in the sector lasts, ALNY may add to its higher timeframe success. Of the 20 analyst ratings, 13 are buys, and seven are a "hold," placing the stock as a moderate buy. Its consensus price target of $229.90 forecasts a staggering 29.70% upside for the stock.

→ This is the #1 Stock to Buy for the AI Tidal Wave (From Chaikin Analytics) (Ad)

Should you invest $1,000 in Regeneron Pharmaceuticals right now?

Before you consider Regeneron Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.

While Regeneron Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
iShares Biotechnology ETF (IBB)N/A$139.16+0.7%0.25%N/AN/AN/A
Alnylam Pharmaceuticals (ALNY)
4.7855 of 5 stars
$158.66+0.6%N/A-44.57Moderate Buy$216.12
Gilead Sciences (GILD)
4.9929 of 5 stars
$72.95-0.8%4.11%16.21Hold$85.86
Regeneron Pharmaceuticals (REGN)
4.0532 of 5 stars
$989.28+0.8%N/A28.47Moderate Buy$939.05
Compare These Stocks  Add These Stocks to My Watchlist 

Ryan Hasson

About Ryan Hasson

  • Ry.has7@gmail.com

Contributing Author

Technical Analysis, Momentum Trading, Risk Management

Experience

Ryan Hasson has been a contributing writer for MarketBeat since 2023.

Areas of Expertise

Equity research and analysis, technical analysis and price action, market sentiment and underlying themes, risk management and trading psychology

Education

Bachelor of Commerce in Financial Management

Past Experience

Equities trader, Kershner Trading Group, business analysis consultant, SMB Capital

Zoom International: Business Analysis Consultant.


Featured Articles and Offers

Search Headlines: